NAVB News and Press, Navidea Biopharmaceuticals Inc. From 07/28/23

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received written notification from NYSE American LLC ("NYSE American" or the "Exchange...

2023-07-27 18:01:42 ET Navidea Biopharmaceuticals ( NYSE: NAVB ) on Thursday said it had named Craig Dais as its CFO. According to NAVB, Dais has over 30 years of executive experience. NAVB said Dais' hiring aligned with its "Fix, Fund, Propel approach to advancin...

Following the Company’s Fix, Fund, Propel approach, Mr. Dais’s hire strengthens financial expertise, leadership, and oversight, along with continuing Navidea’s focus on advancing innovative technology to market Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ...

Following the Company’s Fix, Fund, Propel approach, the proposal substantially undervalues Navidea and is not in the best interests of stockholders. Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused ...

2023-06-29 09:40:49 ET ProPhase Labs ( NASDAQ: PRPH ) said Thursday it recently made an unsolicited non-binding offer to acquire certain assets from Navidea Biopharmaceuticals ( NAVB ), which was rejected . Navidea ( NAVB ) did not make a counteroffer nor did ...

Continuing the Company’s Fix, Fund, Propel approach, the cash payment from Cardinal Health aligns strategic goals while solidifying immediate capital for funding Phase IIb and Phase III trials. Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the...

2023-06-07 16:05:32 ET Navidea Biopharm press release ( NYSE: NAVB ): Q1 GAAP EPS of -$0.05. Shares +4.75% . For further details see: Navidea Biopharm GAAP EPS of -$0.05

Following recently reported financial results for its first quarter ending March 31, 2023, the Company provides additional insight on performance and objectives in line with its Fix, Fund, Propel approach to advancing its innovative technology to market. Navidea Biopharmaceuticals, Inc....

2023-06-05 05:56:11 ET Navidea Biopharmaceuticals ( NYSE: NAVB ) said it received a notice from the NYSE American for not being in compliance with a rule for continued listing on the exchange. The NYSE notice stated that company’s common stock had been trading...

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received a Notice (the “Notice”) on June 1, 2023...